1,228 episodes

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Research To Practice | Oncology Videos Research To Practice

    • Science
    • 4.6 • 97 Ratings

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

    • video
    Hepatobiliary Cancers | Consensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers

    Hepatobiliary Cancers | Consensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers

    Featuring perspectives from Dr Ahmed Omar Kaseb and Prof Arndt Vogel, including the following topics:
    Introduction: EMERALD-1 — Immune Checkpoint Inhibitor-Based Therapy for Localized HCC Eligible for Embolization (0:00) Optimal Utilization of Immune Checkpoint Inhibitors as First-Line Therapy for Advanced HCC – Dr Kaseb (12:49) Incorporation of Anti-PD-1/PD-L1 Antibody-Based Approaches for Advanced Biliary Tract Cancers (BTCs) — Prof Vogel (40:24) CME information and select publications

    • 1 hr
    • video
    Prostate Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer

    Prostate Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer

    Featuring perspectives from Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Dr Elisabeth I Heath and Dr A Oliver Sartor, moderated by Dr Alan H Bryce, including the following topics:
    Introduction (0:00) Optimizing the Management of Nonmetastatic Prostate Cancer — Dr Aggarwal (1:51) Evidence-Based Selection of Treatment for Metastatic Hormone-Sensitive Prostate Cancer — Dr Antonarakis (25:39) New Considerations with PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Bryce (47:31) Role of Novel Radiopharmaceuticals in Therapy for mCRPC — Dr Sartor (1:10:09) Promising Investigational Approaches for Patients with Prostate Cancer — Dr Heath (1:32:05) CME information and select publications
     

    • 1 hr 52 min
    • video
    Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 4 of a 4-Part Series

    Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 4 of a 4-Part Series

    Featuring perspectives from Dr Bradley J Monk, including the following topics:
    Introduction (0:00) Case: A woman (gBRCA1) in her late 40s, 5 months after surgery and adjuvant paclitaxel/carboplatin for Stage II ovarian cancer, now with a single umbilical metastasis — Kellie E Schneider, MD (9:47) Case: A woman (gBRCA2) in her late 60s with Stage IIIC ovarian cancer after surgery and chemotherapy who has received primary olaparib maintenance for 3 years develops acute myeloid leukemia — Swati Vishwanathan, MD (17:21) Case: A woman in her early 60s presents with Stage IV ovarian cancer (BRCA wild-type, homologous recombination deficiency-positive) — Neil Morganstein, MD (22:53) Case: A woman (gBRCA2) in her late 40s with Stage IIIC primary peritoneal cancer receives carboplatin/paclitaxel after R0 debulking surgery; genetic testing results pending — Karim ElSahwi, MD (27:30) Case: A woman in her early 60s with PMH of breast cancer and with limited recurrence of ovarian cancer (BRCA wild-type, homologous recombination deficiency-positive) after chemotherapy and maintenance niraparib refuses to receive chemotherapy — Gigi Chen, MD (33:06) Case: A woman (gBRCA2) in her mid 60s with high-grade serous carcinoma of the fallopian tube undergoes surgery and chemotherapy/bevacizumab but cannot tolerate a PARP inhibitor and refuses to take another agent — Thomas P Morrissey, MD (40:51) Case: A woman (homologous repair deficiency-positive) in her mid 70s with ovarian cancer and disease progression on EPIK-O trial of alpelisib with olaparib tests positive for folate receptor alpha and receives mirvetuximab soravtansine — Lyndsay J Willmott, MD (45:46) Journal Club with Dr Monk (54:13) CME information and select publications

    • 59 min
    • video
    Colorectal Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on Biomarker Assessment and Related Treatment Decision-Making for Patients with Colorectal Cancer

    Colorectal Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on Biomarker Assessment and Related Treatment Decision-Making for Patients with Colorectal Cancer

    Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Andrea Cercek, Dr Cathy Eng and Dr John Strickler, moderated by Dr Christopher Lieu, including the following topics:
    Introduction (0:00) Optimizing Biomarker Assessment and Treatment for Patients with Metastatic Colorectal Cancer (mCRC) — Dr Eng (2:48) Emerging Role of Biomarker-Based Decision-Making for Patients with Localized CRC — Dr Lieu (28:14) Identification and Clinical Care of Patients with mCRC and a BRAF V600E Mutation — Dr Bekaii-Saab (51:20) Integration of Immune Checkpoint Inhibitors into the Management of Microsatellite Instability-High/Mismatch Repair-Deficient mCRC — Dr Cercek (1:14:34) HER2 and Other Emerging Biomarkers for Targeted Therapy in mCRC — Dr Strickler (1:35:48) CME information and select publications

    • 2 hr
    • video
    Urothelial Bladder Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Urothelial Bladder Cancer

    Urothelial Bladder Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Urothelial Bladder Cancer

    Featuring perspectives from Dr Matthew Milowsky, Dr Peter H O’Donnell, Dr Jonathan E Rosenberg and Dr Arlene Siefker-Radtke, moderated by Dr Evan Y Yu, including the following topics:
    Introduction (0:00) Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Milowsky (2:54) Other Novel Strategies Under Investigation for Nonmetastatic UBC — Dr O’Donnell (25:53) Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg (49:43) Emerging Role of HER2-Targeted Therapy for mUBC — Dr Yu (1:12:03) Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke (1:35:51) CME information and select publications
     
     

    • 1 hr 59 min
    • video
    Gastroesophageal Cancers | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Gastroesophageal Cancers

    Gastroesophageal Cancers | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Gastroesophageal Cancers

    Featuring perspectives from Dr David H Ilson, Dr Rutika Mehta, Dr Markus Moehler and Dr Manish A Shah, moderated by Dr Harry H Yoon, including the following topics:
    Introduction (0:00) Recent Developments in the Management of Localized or Locally Advanced Gastroesophageal Cancers — Dr Ilson (2:02) Incorporation of First-Line Immunotherapeutic Strategies for Patients with Metastatic Gastroesophageal Tumors — Dr Yoon (26:40) Emerging Role of Therapy Targeting Claudin 18.2 in Advanced Gastric/GEJ Adenocarcinoma — Dr Shah (50:10) Current Considerations in the Care of Patients with HER2-Positive Gastroesophageal Cancers — Dr Moehler (1:13:14) Selection and Sequencing of Therapy for Patients with Relapsed/Refractory (R/R) HER2-Negative Gastroesophageal Cancers — Dr Mehta (1:34:54) CME information and select publications

    • 2 hr

Customer Reviews

4.6 out of 5
97 Ratings

97 Ratings

a h/o ,

Valued resource

Relentless in its focus on the general medical oncolgist. An important resource.

obete man ,

Excellent

Since my fellowship training Neil Love has made these presentations the best of the best in staying UpToDate with current and future practice

OKMedStudent ,

RTP is is consistently great

Research to Practice continues to put out well produced clinically relevant content from expert faculty that is applicable to daily oncology practice. It is an invaluable resource for me.

Top Podcasts In Science

Hidden Brain, Shankar Vedantam
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
WNYC Studios
Alie Ward
Neil deGrasse Tyson
Sam Harris

You Might Also Like

Sam and Karine
Research To Practice
Vinay Prasad, MD MPH
Dr Neil Love
Dr Neil Love
Dr Neil Love

More by Research To Practice

Dr Neil Love
Dr Neil Love
Dr Neil Love
Dr Neil Love
Dr Neil Love
Dr Neil Love